



**Changes to the CalOptima Health Medi-Cal Physician Administered Drug (PAD) PA List and
OneCare Formulary
Pharmacy & Therapeutics Committee Meeting
November 16, 2023**

Effective Dates	Brand Name†	Generic Name	Drug Class	Strength	Dosage Form	Committee Action for Medi-Cal PAD PA List	Committee Action for OneCare Formulary
1/1/24	Daybue	trofinetide	Rett syndrome	200 mg/mL	Solution	N/A	PA Required
1/1/24	Skyclarys	omaveloxolone	Friedreich's ataxia	50 mg	Capsule	N/A	PA Required
1/1/24	Zavzpret	Zavegepant	Migraine	10 mg/actuation	Solution	N/A	PA Required QL: 8/30 days
1/1/24	Veozah	fezolinetant	Vasomotor symptoms	45 mg	Tablet	N/A	PA Required QL: 30/30 days
1/1/24	Litfulo	ritlecitinib	Alopecia Areata	50 mg	Capsule	N/A	PA Required QL: 30/30 days
1/1/24	Olumiant	baricitinib	Alopecia Areata	4 mg	Tablet	N/A	PA Required QL: 30/30 days
1/1/24	Adstiladrin	nadofaragene firadenovec-vncg	Antineoplastic	300 billion viral particles/mL	Suspension	PA Required	PA Required NSO
1/1/24	Akeega	abiraterone acetate- niraparib tosylate	Antineoplastic	500 mg-100 mg	Tablet	N/A	PA Required NSO QL: 60/30 days
1/1/24	Elrexio	elranatamab-bcmm	Antineoplastic	44 mg/1.1 mL 76 mg-1.9 mL	Solution	PA Required	PA Required NSO
1/1/24	Ojjaara	momelotinib dihydrochloride	Antineoplastic	100 mg, 150 mg, 200 mg	Tablet	N/A	PA Required NSO
1/1/24	Talvey	talquetamab-tgvs	Antineoplastic	2 mg/mL, 40 mg/mL	Solution	PA Required	PA Required NSO
1/1/24	Vanflyta	quizartinib dihydrochloride	Antineoplastic	17.7 mg, 26.6 mg	Tablet	N/A	PA Required NSO QL: 28/14 days

N/A=Not Applicable, PA = Prior Authorization, QL = Quantity Limit, NSO=New Starts Only